Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: A prospective and multicenter study

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Liu, Hui ^a   Zhai, Xiao ^a   Song, Zhaoyang ^b   Sun, Jing ^a   Xiao, Yang ^c   Nie, Danian ^d   Zhang, Y ^a   Huang, Fen ^a   Zhou, Hongsheng ^a   Fan, Zhiping ^a   Tu, Sanfang ^b   Li, Yonghua ^c   Guo, Xutao ^a   Yu, Guopan ^a   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Busulfan; Fludarabine

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NADROPARIN; NORFLOXACIN; PHENYTOIN; PROSTAGLANDIN E1; SULFAMETHOXAZOLE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; ENCEPHALITIS; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 84873422623     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-15     Document Type: Article

References (30)

1. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. De Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S, Blood 2004 104 3 865 872 10.1182/blood-2003-11-3750 15090449 (Pubitemid 38970586)
2. Hematopoietic stem-cell transplantation. Copelan EA, N Engl J Med 2006 354 17 1813 1826 10.1056/NEJMra052638 16641398
3. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N, Exp Hematol Oncol 2012 1 1 13 10.1186/2162-3619-1-13 23210643
4. Busulfan in hematopoietic stem cell transplantation. Ciurea SO, Andersson BS, Biol Blood Marrow Tr 2009 15 5 523 536 10.1016/j.bbmt.2008.12.489
5. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS, Biol Blood Marrow Tr 2002 8 9 468 476 10.1053/bbmt.2002.v8.pm12374451 (Pubitemid 35174820)
6. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. De Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS, Blood 2004 104 3 857 864 10.1182/blood-2004-02-0414 15073038 (Pubitemid 38970585)
7. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, Samiee S, Chahardovali B, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A, Biol Blood Marrow Tr 2007 40 2 105 110 (Pubitemid 47049482)
8. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Andersson BS, De Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE, Biol Blood Marrow Tr 2008 14 6 672 684 10.1016/j.bbmt.2008.03.009 (Pubitemid 351664062)
9. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, Chung JS, Cho GJ, Yang DH, Lee JJ, Kim YK, Kim HJ, Bone Marrow Transplant 2007 40 6 541 547 10.1038/sj.bmt.1705770 17637692 (Pubitemid 47382124)
10. Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. Lee JH, Choi J, Kwon KA, Lee S, Oh SY, Kwon HC, Kim HJ, Han JY, Kim SH, Korean J Hematol 2010 45 2 102 108 10.5045/kjh.2010.45.2.102 21120188
11. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, Mahmud N, Hurter E, Beri R, Rondelli D, BMT 2008 41 11 935 940 (Pubitemid 351850496)
12. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF, J Hematol Oncol 2010 3 1 36 10.1186/1756-8722-3-36 20925957
13. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A, Leukemia 2006 20 2 322 328 10.1038/sj.leu.2404037 16307018 (Pubitemid 43148672)
14. Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine. Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH, J Clin Oncol 2012 in press
15. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up. Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Nagler A, Leukemia 2010 24 5 1050 1052 10.1038/leu.2010.12 20147978
16. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H, BBMT 2009 15 11 1376 1385
17. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q, J Hematol Oncol 2012 5 46 10.1186/1756-8722-5-46 22856463
18. Regimen-related toxicity in patients undergoing bone marrow transplantation. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED, J Clin Oncol 1988 6 10 1562 1568 3049951 (Pubitemid 19092391)
19. Consensus Conference on Acute GVHD Grading. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED, Bone Marrow Transplant 1994 15 6 825 828
20. Chronic graft-versus-host disease. Horwitz ME, Sullivan KM, Blood Rev 2006 20 1 15 27 10.1016/j.blre.2005.01.007 16426941 (Pubitemid 43106715)
21. Acute myeloid leukemia. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM, J Natl Compr Canc Netw 2012 10 8 984 1021 22878824
22. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T, Blood 2003 101 5 2043 2048 10.1182/blood-2002-06-1860 12406916 (Pubitemid 36237612)
23. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Ozcan M, Ustün C, Akçaǧlayan E, Akan H, Arslan O, Ilhan O, Beksaç M, Gürman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koç H, BMT 2001 27 5 499 505 (Pubitemid 32266499)
24. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Anderson D, DeFor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D, BBMT 2003 9 1 52 59 (Pubitemid 41123054)
25. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Lazzarino M, Orlandi E, Baldanti F, Furione M, Pagnucco G, Astori C, Arcaini L, Viglio A, Paulli M, Gerna G, Bernasconi C, Br J Haematol 1999 107 4 877 882 10.1046/j.1365-2141.1999.01765.x 10606897 (Pubitemid 30020163)
26. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Bainton RD, Byrne JL, Davy BJ, Russell NH, Blood 2002 100 10 3843 3844 10.1182/blood-2002-08-2398 12411329 (Pubitemid 35303965)
27. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Pidala J, Cancer Control 2011 18 4 268 276 21976245
28. GVHD prevention: an ounce is better than a pound. Reddy P, Socie G, Cutler C, Weisdorf D, BBMT 2012 18 1 Suppl 17 26
29. Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission. Jing Y, Li H, Zhao Y, Bo J, Wang S, Wang Q, Huang W, Gao C, Yu L, BMT 2012 in press
30. Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients With Acute Myeloid Leukemia in Remission After Haploidentical Hematopoietic Stem Cell Transplantation. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, Chen H, Chen YH, Huang XJ, BBMT 2012 in press